Cancer Trials Show One Year on Roche’s Herceptin Is Best

Extending treatment with Roche’s breast cancer drug Herceptin to two years from the one year current standard is not worthwhile, trial data showed Monday, but shortening treatment to six months also looks unlikely to benefit patients.
Fox News